Covid-19 vaccines are registered in a central procedure. This means that the European Medicines Agency (EMA) has taken over supervision of their safety. In turn, inspections at the vaccine manufacturer are carried out by the agency from the country where the production facility is located.
The EMA has exchanged information on the safety of these medicinal products with the drug agencies of EU member states throughout the SARS CoV-2 virus pandemic. One of the EMA's communication platforms with national drug agencies is the Rapid Alert System. We explain how the drug agencies communicated through this system in the case of Janssen's vaccine with batch number XD955.
April 2021
In April 2021, the FDA (U.S...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
